Loader

Pathways

PathWhiz ID Pathway Meta Data

PW176457

Pw176457 View Pathway
metabolic

Miconazole Predicted Metabolism Pathway

Homo sapiens
Metabolites of Miconazole are predicted with biotransformer.

PW146768

Pw146768 View Pathway
drug action

Microcrystalline cellulose Drug Metabolism Action Pathway

Homo sapiens

PW146634

Pw146634 View Pathway
drug action

Micronomicin Drug Metabolism Action Pathway

Homo sapiens

PW176271

Pw176271 View Pathway
metabolic

Micronomicin Predicted Metabolism Pathway

Homo sapiens
Metabolites of Micronomicin are predicted with biotransformer.

PW126588

Pw126588 View Pathway
drug action

Midazolam Action Pathway

Homo sapiens
Midazolam is a short-acting injectable benzodiazepine with rapid onset that is commonly used in seizures, anesthesia and anxiety disorders. Midazolam allosterically binds on the benzodiazepine receptors in the post-synaptic GABA-A ligand-gated chloride channel in different sites of the central nervous system (CNS). This binding will result in an increase on the GABA inhibitory effects which is translated as an increase in the flow of chloride ions into the cell causing hyperpolarization and stabilization of the cellular plasma membrane. Benzodiazepine receptor associated GABA(a) receptors exist both peripherally and in the CNS, this activity consequently facilitates various effects like sedation, hypnosis, skeletal muscle relaxation, anticonvulsant activity, and anxiolytic action. Midazolam is administered in a variety of ways including intravenous and intramuscular injection and as a buccal solution,

PW144795

Pw144795 View Pathway
drug action

Midazolam Drug Metabolism Action Pathway

Homo sapiens

PW144342

Pw144342 View Pathway
drug action

Midodrine Drug Metabolism Action Pathway

Homo sapiens

PW128515

Pw128515 View Pathway
drug action

Midostaurin Action Pathway

Homo sapiens
Midostaurin, marketed as Rydapt, is an antineoplastic agent employed in the treatment of high-risk acute myeloid leukemia (AML) with specific mutations, aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematologic neoplasm (SM-AHN), or mast cell leukemia (MCL). Primarily, it serves as a multitarget kinase inhibitor, particularly for adult patients with newly diagnosed AML who possess the FLT3 genetic mutation. Approved in April 2017, Midostaurin has demonstrated its ability to improve overall survival rates when used as an adjunct therapy alongside chemotherapeutic agents in AML patients. Its mechanism of action involves targeting multiple receptor tyrosine kinases, including protein kinase C alpha (PKCalpha), VEGFR2, KIT, PDGFR, and WT and/or mutant FLT3 tyrosine kinases. By inhibiting these kinases, Midostaurin disrupts signaling cascades that lead to malignancies such as AML and ASM, ultimately inducing apoptosis in leukemia cells and mast cells. Moreover, Midostaurin has shown effectiveness as a combination therapy during chemotherapy, further enhancing its therapeutic value.

PW145721

Pw145721 View Pathway
drug action

Midostaurin Drug Metabolism Action Pathway

Homo sapiens

PW146661

Pw146661 View Pathway
drug action

Mifamurtide Drug Metabolism Action Pathway

Homo sapiens